Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) stock jumped 360.47% on Friday to $19.80 against a previous-day closing price of $4.30. With 28.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $28.11 whereas the lowest price it dropped to was $4.17. The 52-week range on QNRX shows that it touched its highest point at $444.00 and its lowest point at $3.58 during that stretch. It currently has a 1-year price target of $4.16. Beta for the stock currently stands at 1.69.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QNRX was up-trending over the past week, with a rise of 309.41%, but this was up by 191.98% over a month. Three-month performance surged to 93.31% while six-month performance rose 2.19%. The stock lost -90.41% in the past year, while it has lost -12.97% so far this year. A look at the trailing 12-month EPS for QNRX yields -8.43 with Next year EPS estimates of -1.07.
Float and Shares Shorts:
At present, 8.35 million QNRX shares are outstanding with a float of 5.37 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.99 million, which was 9.83% higher than short shares on Jun 14, 2022. In addition to Dr. Michael Myers Ph.D. as the firm’s Co-Founder, CEO & Chairman, Ms. Denise Carter serves as its Co-Founder, COO & Director.
Through their ownership of 11.42% of QNRX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold — of QNRX, in contrast to — held by mutual funds. Shares owned by individuals account for –.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for QNRX since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With QNRX analysts setting a high price target of $100.00 and a low target of $25.00, the average target price over the next 12 months is $50.00. Based on these targets, QNRX could surge 405.05% to reach the target high and rise by 26.26% to reach the target low. Reaching the average price target will result in a growth of 152.53% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. QNRX will report FY 2022 earnings on 03/27/2023. Analysts have provided yearly estimates in a range of -$6.50 being high and -$187.38 being low. For QNRX, this leads to a yearly average estimate of -$68.71. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Quoin Pharmaceuticals Ltd. surprised analysts by $0.88 when it reported -$2.50 EPS against a consensus estimate of -$3.38. The surprise factor in the prior quarter was -$12.08. Based on analyst estimates, the high estimate for the next quarter is -$1.13 and the low estimate is -$45.50. The average estimate for the next quarter is thus -$16.46.